NewAmsterdam Pharma Company N.V (NAMS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

NewAmsterdam Pharma Company N.V

NasdaqGM•Healthcare•Biotechnology

$21.93+0.75(0.04%)After hours

Market Cap

$2.71B

P/S

379.9x

P/B

4.3x

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

How this company scores

WeakMetricSide Score: 32/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (2/25).

Profitability11/25

Growth2/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality4/25

Strengths

Long cash runwayInterest easily coveredNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 379.9x5y range 33.5x – 379.9x

Currently above its 8-quarter median.

P/B · 4.3x5y range 2.8x – 6.1x

Currently near its 11-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.71B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $7.12M
Q. Revenue: $3.70M
TTM EBITDA: $-244.05M
TTM Op. Income: $-244.41M
Q. Op. Income: $-64.86M
TTM Net Income: $-259.50M
Q. Net Income: $-64.14M
EPS: $-0.52
Shares Out.: $123.37M

$7.12M in TTM revenue declined 88.9% YoY, reaching $3.70M last quarter. TTM EBITDA of $-244.05M and TTM operating income of $-244.41M show growth is flowing through to the bottom line. However, net income is negative at $259.50M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 89% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -1751.0%
Op. Margin: -1752.6%
Net Margin: -1732.9%

Op. margin of -1752.6% is down 1566.5% YoY — costs are rising relative to revenue. Net margin at -1732.9% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 379.9x
P/B Ratio: 4.3x

P/S of 379.9x and P/B of 4.3x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $704.45M
Cash: $424.15M
Long-Term Debt: N/A
Book Value: $631.42M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-39.21M
TTM Free Cash Flow: $-143.72M
FCF Margin: -2018.3%
FCF / Net Income: 0.6

TTM FCF of $-143.72M on $-39.21M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 16% — a weakening trend.